Timeline: International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy “Top line results from the study are expected to be available in 3rd Quarter of 2021 and will help to characterize the potential benefits and risks of Verdiperstat in MSA....
Multiple System Atrophy (MSA) is a rare brain disorder that until recently was largely ignored by the research community. MSA is a rapidly progressing neurodegenerative disease caused by a decline of the body’s most basic and vital functions including...
Recent Comments